Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$1.58 ▼ -0.05
(-3.07%)
MKT CAP: $420.5M • VOL: 2.35M
52W L $1 52W H $3
AUTL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $75.4M | $10.1M | $1.7M |
| YoY Revenue Growth % | +644.9% | +496.0% | — |
| Gross Profit | -$21.0M | -$1.3M | — |
| Gross Margin % | -27.8% | -12.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$270.5M | -$241.4M | -$179.7M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$287.5M | -$220.7M | -$208.4M |
| EBITDA (Normalized) | -$255.3M | -$223.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$283.6M | -$206.3M | -$145.6M |
| Capital Expenditures (CapEx) | $19.0M | $22.1M | — |
| Free Cash Flow (FCF) | -$302.6M | -$228.3M | -$145.6M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $104.1M | $227.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $178.1M | $427.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AUTL.